Vaccination response in lymphoma patients treated with CHOP and rituximab

Withdrawn

Conditions: B-cell malignancy
lymph node cancer
10025320
10004018

Registration Number: NL-OMON32777

Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Withdrawn

Sex: Not specified

Target Recruitment: 140

Inclusion Criteria

- Patients with non-Hodgkin's lymphoma, treated with rituximab (approximately 6-8 cycles) and who are in remission.
- Completion of rituximab therapy in the last twelve months before start of the study
- Age 18 years or older
- Signing of informed consent

Exclusion Criteria

- Vaccination with Hib or pneumococcal vaccine in the last fifteen months before start of the study
- Fever at time of vaccination
- Previous/known allergic reaction to any of the components of the vaccines given

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Antibody titres against S. pneumoniae and H. influenzae type b (in µg/mL) and<br /><br>the influenza virus before and after vaccination. The association between the<br /><br>reconstitution of immune function after treatment with rituximab (in terms of<br /><br>amount of B-cells and immunoglobulin levels) and the rise in antibody titre.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>o The effect of the use of growth factor during chemotherapy on the response to<br /><br>vaccination<br /><br>o The relationship between time since last rituximab-dose and the rise in<br /><br>antibody titre </p><br>